Featured Article
Quest Diagnostics, a U.S. healthcare diagnostic company, had a positive FY 2024. Revenue rose 6.7% to $9.87 billion, and earnings before interest and taxes rose 6.7% to $1.34 billion over the last year. A review of Quest Diagnostics’ 30 January 2025 earnings call and associated financial reports provided insight regarding the importance of pricing on performance. FACTS FROM EARNINGS CALL AND ANNUAL REPORT Pricing was not a topic discussed in their earnings…
Read MoreIn This Issue
Bristol-Myers Squibb, a global biopharmaceutical company, had a mixed FY 2024. Revenue rose 7.3% to $48.3 billion while operating earnings fell 199%…
Read More
Regeneron, a biotechnology company, had a mixed FY 2024. Revenue rose 8.3% to $14.2 billion, while operating profit fell 3.6% to $4.0…
Read More
Baxter, a global healthcare product company, had a mixed FY 2024. Revenue rose 2.7% to $10.6 billion, while operating income fell 98%…
Read More
Challenge Our pricing is challenged by discipline and predictability in capturing our fair share of the value we deliver to customers. Recommendation…
Read More